Monday - February 2, 2026
Novel Agent Ianalumab Added to Standard Therapy Extends Time to Treatment Failure in Patients with Previously Treated Immune Thrombocytopenia
December 09, 2025
WASHINGTON, Dec. 9 [Category: Medical] -- The American Society of Hematology posted the following news release:

* * *

Novel Agent Ianalumab Added to Standard Therapy Extends Time to Treatment Failure in Patients with Previously Treated Immune Thrombocytopenia

*

LBA-2: Primary results from VAYHIT2, a randomized, double-blind, phase 3 trial of ianalumab plus eltrombopag versus placebo plus eltrombopag in patients with primary immune thrombocytope . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products